#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Biomedical applications of metallic oxide nanoparticles are recently considered an interesting avenue of research regarding nano-biotechnology .
2-1	16-26	Biomedical	abstract[2]	new[2]	coref	3-16[11_2]
2-2	27-39	applications	abstract[2]	new[2]	_	_
2-3	40-42	of	abstract[2]	new[2]	_	_
2-4	43-51	metallic	abstract[2]|object[4]	new[2]|new[4]	ana	3-12[0_4]
2-5	52-57	oxide	abstract[2]|substance|object[4]	new[2]|new|new[4]	coref	4-10[19_0]
2-6	58-71	nanoparticles	abstract[2]|object[4]	new[2]|new[4]	_	_
2-7	72-75	are	_	_	_	_
2-8	76-84	recently	_	_	_	_
2-9	85-95	considered	_	_	_	_
2-10	96-98	an	abstract[5]	new[5]	_	_
2-11	99-110	interesting	abstract[5]	new[5]	_	_
2-12	111-117	avenue	abstract[5]	new[5]	_	_
2-13	118-120	of	abstract[5]	new[5]	_	_
2-14	121-129	research	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-15	130-139	regarding	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-16	140-158	nano-biotechnology	abstract[5]|abstract[6]|object	new[5]|new[6]|new	_	_
2-17	159-160	.	_	_	_	_

#Text=Nanoparticles possess unique physio-chemical , optical and electro-magnetic properties that make them appropriate tools for various applications in the field of materials science and pharmacy .
3-1	161-174	Nanoparticles	substance	new	_	_
3-2	175-182	possess	_	_	_	_
3-3	183-189	unique	abstract[9]	new[9]	coref	13-3[97_9]
3-4	190-205	physio-chemical	abstract[9]	new[9]	_	_
3-5	206-207	,	abstract[9]	new[9]	_	_
3-6	208-215	optical	abstract[9]	new[9]	_	_
3-7	216-219	and	abstract[9]	new[9]	_	_
3-8	220-236	electro-magnetic	abstract[9]	new[9]	_	_
3-9	237-247	properties	abstract[9]	new[9]	_	_
3-10	248-252	that	abstract[9]	new[9]	_	_
3-11	253-257	make	abstract[9]	new[9]	_	_
3-12	258-262	them	abstract[9]|object	new[9]|giv	coref	4-10[20_0]
3-13	263-274	appropriate	abstract[9]	new[9]	_	_
3-14	275-280	tools	abstract[9]	new[9]	_	_
3-15	281-284	for	abstract[9]	new[9]	_	_
3-16	285-292	various	abstract[9]|abstract[11]	new[9]|giv[11]	coref	13-20[105_11]
3-17	293-305	applications	abstract[9]|abstract[11]	new[9]|giv[11]	_	_
3-18	306-308	in	abstract[9]|abstract[11]	new[9]|giv[11]	_	_
3-19	309-312	the	abstract[9]|abstract[11]|abstract[12]	new[9]|giv[11]|new[12]	_	_
3-20	313-318	field	abstract[9]|abstract[11]|abstract[12]	new[9]|giv[11]|new[12]	_	_
3-21	319-321	of	abstract[9]|abstract[11]|abstract[12]	new[9]|giv[11]|new[12]	_	_
3-22	322-331	materials	abstract[9]|abstract[11]|abstract[12]|substance|abstract[14]	new[9]|giv[11]|new[12]|new|new[14]	_	_
3-23	332-339	science	abstract[9]|abstract[11]|abstract[12]|abstract[14]	new[9]|giv[11]|new[12]|new[14]	_	_
3-24	340-343	and	abstract[9]|abstract[11]|abstract[12]	new[9]|giv[11]|new[12]	_	_
3-25	344-352	pharmacy	abstract[9]|abstract[11]|abstract[12]|abstract	new[9]|giv[11]|new[12]|new	_	_
3-26	353-354	.	_	_	_	_

#Text=Co-precipitation is the most adaptive method for preparation of metallic oxide nanoparticles because of its reproducibility and cheapness .
4-1	355-371	Co-precipitation	abstract	new	coref	4-3[17_0]
4-2	372-374	is	_	_	_	_
4-3	375-378	the	abstract[17]	giv[17]	ana	4-15[0_17]
4-4	379-383	most	abstract[17]	giv[17]	_	_
4-5	384-392	adaptive	abstract[17]	giv[17]	_	_
4-6	393-399	method	abstract[17]	giv[17]	_	_
4-7	400-403	for	abstract[17]	giv[17]	_	_
4-8	404-415	preparation	abstract[17]|abstract[18]	giv[17]|new[18]	_	_
4-9	416-418	of	abstract[17]|abstract[18]	giv[17]|new[18]	_	_
4-10	419-427	metallic	abstract[17]|abstract[18]|substance[19]|object[20]	giv[17]|new[18]|giv[19]|giv[20]	coref	5-6[0_20]
4-11	428-433	oxide	abstract[17]|abstract[18]|substance[19]|object[20]	giv[17]|new[18]|giv[19]|giv[20]	_	_
4-12	434-447	nanoparticles	abstract[17]|abstract[18]|object[20]	giv[17]|new[18]|giv[20]	_	_
4-13	448-455	because	abstract[17]	giv[17]	_	_
4-14	456-458	of	abstract[17]	giv[17]	_	_
4-15	459-462	its	abstract[17]|abstract|abstract[22]	giv[17]|giv|new[22]	_	_
4-16	463-478	reproducibility	abstract[17]|abstract[22]	giv[17]|new[22]	_	_
4-17	479-482	and	abstract[17]	giv[17]	_	_
4-18	483-492	cheapness	abstract[17]|abstract	giv[17]|new	_	_
4-19	493-494	.	_	_	_	_

#Text=Titanium dioxide ( TiO2 ) nanoparticles have been vastly synthesized by different chemical routes .
5-1	495-503	Titanium	person|abstract[25]	new|new[25]	appos	5-4[0_25]
5-2	504-511	dioxide	abstract[25]	new[25]	_	_
5-3	512-513	(	_	_	_	_
5-4	514-518	TiO2	abstract	giv	coref	7-3
5-5	519-520	)	_	_	_	_
5-6	521-534	nanoparticles	object	giv	coref	6-5
5-7	535-539	have	_	_	_	_
5-8	540-544	been	_	_	_	_
5-9	545-551	vastly	_	_	_	_
5-10	552-563	synthesized	_	_	_	_
5-11	564-566	by	_	_	_	_
5-12	567-576	different	abstract[28]	new[28]	_	_
5-13	577-585	chemical	abstract[28]	new[28]	_	_
5-14	586-592	routes	abstract[28]	new[28]	_	_
5-15	593-594	.	_	_	_	_

#Text=Doping prevents aggregation between nanoparticles ultimately leading to their stability , longevity as well as intensified reactivity .
6-1	595-601	Doping	abstract	new	_	_
6-2	602-610	prevents	_	_	_	_
6-3	611-622	aggregation	event[30]	new[30]	_	_
6-4	623-630	between	event[30]	new[30]	_	_
6-5	631-644	nanoparticles	event[30]|object	new[30]|giv	ana	6-9
6-6	645-655	ultimately	_	_	_	_
6-7	656-663	leading	_	_	_	_
6-8	664-666	to	_	_	_	_
6-9	667-672	their	object|abstract[33]	giv|new[33]	coref	7-3[37_0]
6-10	673-682	stability	abstract[33]	new[33]	_	_
6-11	683-684	,	_	_	_	_
6-12	685-694	longevity	abstract	new	_	_
6-13	695-697	as	_	_	_	_
6-14	698-702	well	_	_	_	_
6-15	703-705	as	_	_	_	_
6-16	706-717	intensified	event[35]	new[35]	_	_
6-17	718-728	reactivity	event[35]	new[35]	_	_
6-18	729-730	.	_	_	_	_

#Text=Hence , TiO2 nanoparticles have been doped with Ni , Cu , Fe , Mo , N and other metals using hydrolysis , precipitation , sol-gel and other methods for fabrication in the past .
7-1	731-736	Hence	_	_	_	_
7-2	737-738	,	_	_	_	_
7-3	739-743	TiO2	abstract|object[37]	giv|giv[37]	coref|coref	8-2|8-1[52_37]
7-4	744-757	nanoparticles	object[37]	giv[37]	_	_
7-5	758-762	have	_	_	_	_
7-6	763-767	been	_	_	_	_
7-7	768-773	doped	_	_	_	_
7-8	774-778	with	_	_	_	_
7-9	779-781	Ni	person	new	_	_
7-10	782-783	,	_	_	_	_
7-11	784-786	Cu	person	new	coref	11-9
7-12	787-788	,	_	_	_	_
7-13	789-791	Fe	person	new	coref	11-11
7-14	792-793	,	_	_	_	_
7-15	794-796	Mo	person	new	_	_
7-16	797-798	,	_	_	_	_
7-17	799-800	N	substance	new	_	_
7-18	801-804	and	_	_	_	_
7-19	805-810	other	substance[43]	new[43]	_	_
7-20	811-817	metals	substance[43]	new[43]	_	_
7-21	818-823	using	_	_	_	_
7-22	824-834	hydrolysis	abstract|abstract[45]	new|new[45]	ana	8-18[0_45]
7-23	835-836	,	abstract[45]	new[45]	_	_
7-24	837-850	precipitation	abstract[45]|substance	new[45]|new	_	_
7-25	851-852	,	abstract[45]	new[45]	_	_
7-26	853-860	sol-gel	abstract[45]|substance	new[45]|new	_	_
7-27	861-864	and	abstract[45]	new[45]	_	_
7-28	865-870	other	abstract[45]|abstract[48]	new[45]|new[48]	_	_
7-29	871-878	methods	abstract[45]|abstract[48]	new[45]|new[48]	_	_
7-30	879-882	for	abstract[45]|abstract[48]	new[45]|new[48]	_	_
7-31	883-894	fabrication	abstract[45]|abstract[48]|animal	new[45]|new[48]|new	_	_
7-32	895-897	in	_	_	_	_
7-33	898-901	the	time[50]	new[50]	_	_
7-34	902-906	past	time[50]	new[50]	_	_
7-35	907-908	.	_	_	_	_

#Text=Metal-doped TiO2 nanoparticles serve many environmental remediation purposes like removal of organic dyes and wastes/pollutants owing to their tremendous photocatalytic activity .
8-1	909-920	Metal-doped	object[52]	giv[52]	coref	9-15[69_52]
8-2	921-925	TiO2	abstract|object[52]	giv|giv[52]	coref	9-12[66_0]
8-3	926-939	nanoparticles	object[52]	giv[52]	_	_
8-4	940-945	serve	_	_	_	_
8-5	946-950	many	abstract[54]	new[54]	ana	9-4[0_54]
8-6	951-964	environmental	abstract[54]	new[54]	_	_
8-7	965-976	remediation	abstract|abstract[54]	new|new[54]	_	_
8-8	977-985	purposes	abstract[54]	new[54]	_	_
8-9	986-990	like	abstract[54]	new[54]	_	_
8-10	991-998	removal	abstract[54]|event[55]	new[54]|new[55]	_	_
8-11	999-1001	of	abstract[54]|event[55]	new[54]|new[55]	_	_
8-12	1002-1009	organic	abstract[54]|event[55]|substance[56]	new[54]|new[55]|new[56]	_	_
8-13	1010-1014	dyes	abstract[54]|event[55]|substance[56]	new[54]|new[55]|new[56]	_	_
8-14	1015-1018	and	abstract[54]|event[55]	new[54]|new[55]	_	_
8-15	1019-1036	wastes/pollutants	abstract[54]|event[55]|substance	new[54]|new[55]|new	_	_
8-16	1037-1042	owing	abstract[54]|event[55]	new[54]|new[55]	_	_
8-17	1043-1045	to	abstract[54]|event[55]	new[54]|new[55]	_	_
8-18	1046-1051	their	abstract[54]|event[55]|abstract|abstract[59]	new[54]|new[55]|giv|new[59]	coref	9-9[64_59]
8-19	1052-1062	tremendous	abstract[54]|event[55]|abstract[59]	new[54]|new[55]|new[59]	_	_
8-20	1063-1077	photocatalytic	abstract[54]|event[55]|abstract[59]	new[54]|new[55]|new[59]	_	_
8-21	1078-1086	activity	abstract[54]|event[55]|abstract[59]	new[54]|new[55]|new[59]	_	_
8-22	1087-1088	.	_	_	_	_

#Text=In context of their role in biomedicine , antibacterial activity of Mn-doped TiO2 and Nd-doped TiO2 nanoparticles has been documented .
9-1	1089-1091	In	_	_	_	_
9-2	1092-1099	context	abstract[60]	new[60]	_	_
9-3	1100-1102	of	abstract[60]	new[60]	_	_
9-4	1103-1108	their	abstract[60]|abstract|abstract[62]	new[60]|giv|new[62]	coref	18-12[144_62]
9-5	1109-1113	role	abstract[60]|abstract[62]	new[60]|new[62]	_	_
9-6	1114-1116	in	abstract[60]|abstract[62]	new[60]|new[62]	_	_
9-7	1117-1128	biomedicine	abstract[60]|abstract[62]|abstract	new[60]|new[62]|new	coref	18-23
9-8	1129-1130	,	_	_	_	_
9-9	1131-1144	antibacterial	abstract[64]	giv[64]	_	_
9-10	1145-1153	activity	abstract[64]	giv[64]	_	_
9-11	1154-1156	of	abstract[64]	giv[64]	_	_
9-12	1157-1165	Mn-doped	abstract[64]|animal|abstract[66]	giv[64]|new|giv[66]	coref	9-15[68_66]
9-13	1166-1170	TiO2	abstract[64]|abstract[66]	giv[64]|giv[66]	_	_
9-14	1171-1174	and	abstract[64]	giv[64]	_	_
9-15	1175-1183	Nd-doped	abstract[64]|animal|abstract[68]|object[69]	giv[64]|new|giv[68]|giv[69]	coref|coref	10-1[0_68]|10-1[71_69]
9-16	1184-1188	TiO2	abstract[64]|abstract[68]|object[69]	giv[64]|giv[68]|giv[69]	_	_
9-17	1189-1202	nanoparticles	abstract[64]|object[69]	giv[64]|giv[69]	_	_
9-18	1203-1206	has	_	_	_	_
9-19	1207-1211	been	_	_	_	_
9-20	1212-1222	documented	_	_	_	_
9-21	1223-1224	.	_	_	_	_

#Text=TiO2 nanoparticles have been proven important skin protecting agents against UV radiation and used in sunscreens/cosmetics as reported by Viana et al. .
10-1	1225-1229	TiO2	abstract|object[71]	giv|giv[71]	coref|coref	11-3|11-3[80_71]
10-2	1230-1243	nanoparticles	object[71]	giv[71]	_	_
10-3	1244-1248	have	_	_	_	_
10-4	1249-1253	been	_	_	_	_
10-5	1254-1260	proven	_	_	_	_
10-6	1261-1270	important	substance[73]	new[73]	coref	20-23[162_73]
10-7	1271-1275	skin	object|substance[73]	new|new[73]	_	_
10-8	1276-1286	protecting	substance[73]	new[73]	_	_
10-9	1287-1293	agents	substance[73]	new[73]	_	_
10-10	1294-1301	against	substance[73]	new[73]	_	_
10-11	1302-1304	UV	substance[73]|substance|abstract[75]	new[73]|new|new[75]	_	_
10-12	1305-1314	radiation	substance[73]|abstract[75]	new[73]|new[75]	_	_
10-13	1315-1318	and	_	_	_	_
10-14	1319-1323	used	_	_	_	_
10-15	1324-1326	in	_	_	_	_
10-16	1327-1347	sunscreens/cosmetics	object	new	_	_
10-17	1348-1350	as	_	_	_	_
10-18	1351-1359	reported	_	_	_	_
10-19	1360-1362	by	_	_	_	_
10-20	1363-1368	Viana	person	new	_	_
10-21	1369-1371	et	_	_	_	_
10-22	1372-1375	al.	_	_	_	_
10-23	1376-1377	.	_	_	_	_

#Text=Cytotoxicity of TiO2 nanoparticles doped with Ag , Cu , Fe has been validated against human cancer cell lines and hence these nanoparticles have been successfully declared anti-cancerous materials .
11-1	1378-1390	Cytotoxicity	substance[78]	new[78]	_	_
11-2	1391-1393	of	substance[78]	new[78]	_	_
11-3	1394-1398	TiO2	substance[78]|abstract|object[80]	new[78]|giv|giv[80]	coref|coref	11-22[87_80]|12-10
11-4	1399-1412	nanoparticles	substance[78]|object[80]	new[78]|giv[80]	_	_
11-5	1413-1418	doped	substance[78]|object[80]	new[78]|giv[80]	_	_
11-6	1419-1423	with	substance[78]|object[80]	new[78]|giv[80]	_	_
11-7	1424-1426	Ag	substance[78]|object[80]|substance	new[78]|giv[80]|new	_	_
11-8	1427-1428	,	substance[78]|object[80]	new[78]|giv[80]	_	_
11-9	1429-1431	Cu	substance[78]|object[80]|person	new[78]|giv[80]|giv	_	_
11-10	1432-1433	,	substance[78]|object[80]	new[78]|giv[80]	_	_
11-11	1434-1436	Fe	substance[78]|object[80]|person	new[78]|giv[80]|giv	_	_
11-12	1437-1440	has	_	_	_	_
11-13	1441-1445	been	_	_	_	_
11-14	1446-1455	validated	_	_	_	_
11-15	1456-1463	against	_	_	_	_
11-16	1464-1469	human	object[86]	new[86]	_	_
11-17	1470-1476	cancer	abstract|object[86]	new|new[86]	coref	16-13
11-18	1477-1481	cell	place|object[86]	new|new[86]	coref	15-12
11-19	1482-1487	lines	object[86]	new[86]	_	_
11-20	1488-1491	and	_	_	_	_
11-21	1492-1497	hence	_	_	_	_
11-22	1498-1503	these	object[87]	giv[87]	coref	12-9[93_87]
11-23	1504-1517	nanoparticles	object[87]	giv[87]	_	_
11-24	1518-1522	have	_	_	_	_
11-25	1523-1527	been	_	_	_	_
11-26	1528-1540	successfully	_	_	_	_
11-27	1541-1549	declared	_	_	_	_
11-28	1550-1564	anti-cancerous	_	_	_	_
11-29	1565-1574	materials	_	_	_	_
11-30	1575-1576	.	_	_	_	_

#Text=Regarding bioremediation studies , the photocatalytic property of N-doped TiO2 nanoparticles for air and water purification was exclusively described .
12-1	1577-1586	Regarding	_	_	_	_
12-2	1587-1601	bioremediation	abstract|abstract[89]	new|new[89]	_	_
12-3	1602-1609	studies	abstract[89]	new[89]	_	_
12-4	1610-1611	,	_	_	_	_
12-5	1612-1615	the	abstract[90]	new[90]	_	_
12-6	1616-1630	photocatalytic	abstract[90]	new[90]	_	_
12-7	1631-1639	property	abstract[90]	new[90]	_	_
12-8	1640-1642	of	abstract[90]	new[90]	_	_
12-9	1643-1650	N-doped	abstract[90]|animal|object[93]	new[90]|new|giv[93]	coref|coref	13-16|13-16[103_93]
12-10	1651-1655	TiO2	abstract[90]|abstract|object[93]	new[90]|giv|giv[93]	coref	13-17
12-11	1656-1669	nanoparticles	abstract[90]|object[93]	new[90]|giv[93]	_	_
12-12	1670-1673	for	abstract[90]|object[93]	new[90]|giv[93]	_	_
12-13	1674-1677	air	abstract[90]|object[93]|substance	new[90]|giv[93]|new	_	_
12-14	1678-1681	and	abstract[90]|object[93]	new[90]|giv[93]	_	_
12-15	1682-1687	water	abstract[90]|object[93]|substance|substance[96]	new[90]|giv[93]|new|new[96]	_	_
12-16	1688-1700	purification	abstract[90]|object[93]|substance[96]	new[90]|giv[93]|new[96]	_	_
12-17	1701-1704	was	_	_	_	_
12-18	1705-1716	exclusively	_	_	_	_
12-19	1717-1726	described	_	_	_	_
12-20	1727-1728	.	_	_	_	_

#Text=Talking about biomedical properties , Zane et al. reported the biocompatibility and antibacterial activity of N-doped TiO2 nanoparticles and its applications in dental resin formulations .
13-1	1729-1736	Talking	_	_	_	_
13-2	1737-1742	about	_	_	_	_
13-3	1743-1753	biomedical	abstract[97]	giv[97]	_	_
13-4	1754-1764	properties	abstract[97]	giv[97]	_	_
13-5	1765-1766	,	_	_	_	_
13-6	1767-1771	Zane	person	new	_	_
13-7	1772-1774	et	_	_	_	_
13-8	1775-1778	al.	_	_	_	_
13-9	1779-1787	reported	_	_	_	_
13-10	1788-1791	the	abstract[99]	new[99]	coref	15-16[124_99]
13-11	1792-1808	biocompatibility	abstract[99]	new[99]	_	_
13-12	1809-1812	and	_	_	_	_
13-13	1813-1826	antibacterial	abstract[100]	new[100]	ana	13-20[0_100]
13-14	1827-1835	activity	abstract[100]	new[100]	_	_
13-15	1836-1838	of	abstract[100]	new[100]	_	_
13-16	1839-1846	N-doped	abstract[100]|animal|object[103]	new[100]|giv|giv[103]	coref|coref	14-10|14-10[112_103]
13-17	1847-1851	TiO2	abstract[100]|abstract|object[103]	new[100]|giv|giv[103]	coref	14-11
13-18	1852-1865	nanoparticles	abstract[100]|object[103]	new[100]|giv[103]	_	_
13-19	1866-1869	and	_	_	_	_
13-20	1870-1873	its	abstract|abstract[105]	giv|giv[105]	_	_
13-21	1874-1886	applications	abstract[105]	giv[105]	_	_
13-22	1887-1889	in	abstract[105]	giv[105]	_	_
13-23	1890-1896	dental	abstract[105]|substance[106]|substance[107]	giv[105]|new[106]|new[107]	_	_
13-24	1897-1902	resin	abstract[105]|substance[106]|substance[107]	giv[105]|new[106]|new[107]	_	_
13-25	1903-1915	formulations	abstract[105]|substance[107]	giv[105]|new[107]	_	_
13-26	1916-1917	.	_	_	_	_

#Text=Moreover , the assessment of orthodontic brackets coated with N-doped TiO2 nanoparticles against Streptococcus mutans was illuminated by Salehi et al. .
14-1	1918-1926	Moreover	_	_	_	_
14-2	1927-1928	,	_	_	_	_
14-3	1929-1932	the	abstract[108]	new[108]	_	_
14-4	1933-1943	assessment	abstract[108]	new[108]	_	_
14-5	1944-1946	of	abstract[108]	new[108]	_	_
14-6	1947-1958	orthodontic	abstract[108]|object[109]	new[108]|new[109]	_	_
14-7	1959-1967	brackets	abstract[108]|object[109]	new[108]|new[109]	_	_
14-8	1968-1974	coated	abstract[108]|object[109]	new[108]|new[109]	_	_
14-9	1975-1979	with	abstract[108]|object[109]	new[108]|new[109]	_	_
14-10	1980-1987	N-doped	abstract[108]|object[109]|animal|object[112]	new[108]|new[109]|giv|giv[112]	coref|coref	15-8|15-8[120_112]
14-11	1988-1992	TiO2	abstract[108]|object[109]|abstract|object[112]	new[108]|new[109]|giv|giv[112]	coref	15-9
14-12	1993-2006	nanoparticles	abstract[108]|object[109]|object[112]	new[108]|new[109]|giv[112]	_	_
14-13	2007-2014	against	abstract[108]|object[109]|object[112]	new[108]|new[109]|giv[112]	_	_
14-14	2015-2028	Streptococcus	abstract[108]|object[109]|object[112]|animal|substance[114]	new[108]|new[109]|giv[112]|new|new[114]	_	_
14-15	2029-2035	mutans	abstract[108]|object[109]|object[112]|substance[114]	new[108]|new[109]|giv[112]|new[114]	_	_
14-16	2036-2039	was	_	_	_	_
14-17	2040-2051	illuminated	_	_	_	_
14-18	2052-2054	by	_	_	_	_
14-19	2055-2061	Salehi	person	new	_	_
14-20	2062-2064	et	_	_	_	_
14-21	2065-2068	al.	_	_	_	_
14-22	2069-2070	.	_	_	_	_

#Text=Atchudan et al. explained the applications of N-doped TiO2 nanoparticles in cell imaging due to their good biocompatibility .
15-1	2071-2079	Atchudan	person	new	_	_
15-2	2080-2082	et	_	_	_	_
15-3	2083-2086	al.	_	_	_	_
15-4	2087-2096	explained	_	_	_	_
15-5	2097-2100	the	abstract[117]	new[117]	_	_
15-6	2101-2113	applications	abstract[117]	new[117]	_	_
15-7	2114-2116	of	abstract[117]	new[117]	_	_
15-8	2117-2124	N-doped	abstract[117]|animal|object[120]	new[117]|giv|giv[120]	ana|coref	15-16[0_120]|16-9
15-9	2125-2129	TiO2	abstract[117]|abstract|object[120]	new[117]|giv|giv[120]	coref	16-10
15-10	2130-2143	nanoparticles	abstract[117]|object[120]	new[117]|giv[120]	_	_
15-11	2144-2146	in	abstract[117]|object[120]	new[117]|giv[120]	_	_
15-12	2147-2151	cell	abstract[117]|object[120]|place|abstract[122]	new[117]|giv[120]|giv|new[122]	_	_
15-13	2152-2159	imaging	abstract[117]|object[120]|abstract[122]	new[117]|giv[120]|new[122]	_	_
15-14	2160-2163	due	_	_	_	_
15-15	2164-2166	to	_	_	_	_
15-16	2167-2172	their	object|abstract[124]	giv|giv[124]	coref	16-9[129_0]
15-17	2173-2177	good	abstract[124]	giv[124]	_	_
15-18	2178-2194	biocompatibility	abstract[124]	giv[124]	_	_
15-19	2195-2196	.	_	_	_	_

#Text=Li et al. studied the photokilling effect of N-doped TiO2 nanoparticles on cancer cells .
16-1	2197-2199	Li	person	new	_	_
16-2	2200-2202	et	_	_	_	_
16-3	2203-2206	al.	_	_	_	_
16-4	2207-2214	studied	_	_	_	_
16-5	2215-2218	the	abstract[126]	new[126]	_	_
16-6	2219-2231	photokilling	abstract[126]	new[126]	_	_
16-7	2232-2238	effect	abstract[126]	new[126]	_	_
16-8	2239-2241	of	abstract[126]	new[126]	_	_
16-9	2242-2249	N-doped	abstract[126]|animal|object[129]	new[126]|giv|giv[129]	coref|coref	17-21[139_129]|18-19
16-10	2250-2254	TiO2	abstract[126]|abstract|object[129]	new[126]|giv|giv[129]	coref	17-24
16-11	2255-2268	nanoparticles	abstract[126]|object[129]	new[126]|giv[129]	_	_
16-12	2269-2271	on	_	_	_	_
16-13	2272-2278	cancer	abstract|animal[131]	giv|new[131]	_	_
16-14	2279-2284	cells	animal[131]	new[131]	_	_
16-15	2285-2286	.	_	_	_	_

#Text=The purpose of the present study was to complement the vacuum in literature regarding exploration of comprehensive biological potential of N-doped and undoped TiO2 nanoparticles .
17-1	2287-2290	The	abstract[132]	new[132]	_	_
17-2	2291-2298	purpose	abstract[132]	new[132]	_	_
17-3	2299-2301	of	abstract[132]	new[132]	_	_
17-4	2302-2305	the	abstract[132]|abstract[133]	new[132]|new[133]	_	_
17-5	2306-2313	present	abstract[132]|abstract[133]	new[132]|new[133]	_	_
17-6	2314-2319	study	abstract[132]|abstract[133]	new[132]|new[133]	_	_
17-7	2320-2323	was	_	_	_	_
17-8	2324-2326	to	_	_	_	_
17-9	2327-2337	complement	_	_	_	_
17-10	2338-2341	the	abstract[134]	new[134]	_	_
17-11	2342-2348	vacuum	abstract[134]	new[134]	_	_
17-12	2349-2351	in	abstract[134]	new[134]	_	_
17-13	2352-2362	literature	abstract[134]|abstract[135]	new[134]|new[135]	_	_
17-14	2363-2372	regarding	abstract[134]|abstract[135]	new[134]|new[135]	_	_
17-15	2373-2384	exploration	abstract[134]|abstract[135]|event[136]	new[134]|new[135]|new[136]	_	_
17-16	2385-2387	of	abstract[134]|abstract[135]|event[136]	new[134]|new[135]|new[136]	_	_
17-17	2388-2401	comprehensive	abstract[134]|abstract[135]|event[136]|abstract[137]	new[134]|new[135]|new[136]|new[137]	ana	18-6[0_137]
17-18	2402-2412	biological	abstract[134]|abstract[135]|event[136]|abstract[137]	new[134]|new[135]|new[136]|new[137]	_	_
17-19	2413-2422	potential	abstract[134]|abstract[135]|event[136]|abstract[137]	new[134]|new[135]|new[136]|new[137]	_	_
17-20	2423-2425	of	abstract[134]|abstract[135]|event[136]|abstract[137]	new[134]|new[135]|new[136]|new[137]	_	_
17-21	2426-2433	N-doped	abstract[134]|abstract[135]|event[136]|abstract[137]|object[139]	new[134]|new[135]|new[136]|new[137]|giv[139]	coref	18-15[146_139]
17-22	2434-2437	and	abstract[134]|abstract[135]|event[136]|abstract[137]|object[139]	new[134]|new[135]|new[136]|new[137]|giv[139]	_	_
17-23	2438-2445	undoped	abstract[134]|abstract[135]|event[136]|abstract[137]|object[139]	new[134]|new[135]|new[136]|new[137]|giv[139]	_	_
17-24	2446-2450	TiO2	abstract[134]|abstract[135]|event[136]|abstract[137]|abstract|object[139]	new[134]|new[135]|new[136]|new[137]|giv|giv[139]	coref	18-16
17-25	2451-2464	nanoparticles	abstract[134]|abstract[135]|event[136]|abstract[137]|object[139]	new[134]|new[135]|new[136]|new[137]|giv[139]	_	_
17-26	2465-2466	.	_	_	_	_

#Text=According to our knowledge , this is the first report covering multifunctional role of bare TiO2 nanoparticles and N-doped TiO2 nanoparticles in biomedicine .
18-1	2467-2476	According	_	_	_	_
18-2	2477-2479	to	_	_	_	_
18-3	2480-2483	our	person|abstract[141]	acc|new[141]	_	_
18-4	2484-2493	knowledge	abstract[141]	new[141]	_	_
18-5	2494-2495	,	_	_	_	_
18-6	2496-2500	this	abstract	giv	coref	18-8[143_0]
18-7	2501-2503	is	_	_	_	_
18-8	2504-2507	the	abstract[143]	giv[143]	_	_
18-9	2508-2513	first	abstract[143]	giv[143]	_	_
18-10	2514-2520	report	abstract[143]	giv[143]	_	_
18-11	2521-2529	covering	abstract[143]	giv[143]	_	_
18-12	2530-2545	multifunctional	abstract[143]|abstract[144]	giv[143]|giv[144]	_	_
18-13	2546-2550	role	abstract[143]|abstract[144]	giv[143]|giv[144]	_	_
18-14	2551-2553	of	abstract[143]|abstract[144]	giv[143]|giv[144]	_	_
18-15	2554-2558	bare	abstract[143]|abstract[144]|object[146]|object[147]	giv[143]|giv[144]|giv[146]|giv[147]	coref|coref	18-15[147_146]|18-19[150_147]
18-16	2559-2563	TiO2	abstract[143]|abstract[144]|abstract|object[146]|object[147]	giv[143]|giv[144]|giv|giv[146]|giv[147]	coref	18-20
18-17	2564-2577	nanoparticles	abstract[143]|abstract[144]|object[146]|object[147]	giv[143]|giv[144]|giv[146]|giv[147]	_	_
18-18	2578-2581	and	abstract[143]|abstract[144]|object[147]	giv[143]|giv[144]|giv[147]	_	_
18-19	2582-2589	N-doped	abstract[143]|abstract[144]|object[147]|animal|object[150]	giv[143]|giv[144]|giv[147]|giv|giv[150]	coref	20-4[159_150]
18-20	2590-2594	TiO2	abstract[143]|abstract[144]|object[147]|abstract|object[150]	giv[143]|giv[144]|giv[147]|giv|giv[150]	coref	20-7
18-21	2595-2608	nanoparticles	abstract[143]|abstract[144]|object[147]|object[150]	giv[143]|giv[144]|giv[147]|giv[150]	_	_
18-22	2609-2611	in	abstract[143]|abstract[144]|object[147]|object[150]	giv[143]|giv[144]|giv[147]|giv[150]	_	_
18-23	2612-2623	biomedicine	abstract[143]|abstract[144]|object[147]|object[150]|abstract	giv[143]|giv[144]|giv[147]|giv[150]|giv	_	_
18-24	2624-2625	.	_	_	_	_

#Text=Antibacterial , antifungal , antioxidant , antidiabetic , protein kinase inhibition and cytotoxicity assays have been carried out under in vitro conditions .
19-1	2626-2639	Antibacterial	abstract[155]	new[155]	_	_
19-2	2640-2641	,	abstract[155]	new[155]	_	_
19-3	2642-2652	antifungal	abstract[155]	new[155]	_	_
19-4	2653-2654	,	abstract[155]	new[155]	_	_
19-5	2655-2666	antioxidant	abstract[155]	new[155]	_	_
19-6	2667-2668	,	abstract[155]	new[155]	_	_
19-7	2669-2681	antidiabetic	abstract[155]	new[155]	_	_
19-8	2682-2683	,	abstract[155]	new[155]	_	_
19-9	2684-2691	protein	substance|abstract[153]|abstract[155]	new|new[153]|new[155]	_	_
19-10	2692-2698	kinase	abstract[153]|abstract[155]	new[153]|new[155]	_	_
19-11	2699-2709	inhibition	abstract[153]|abstract[155]	new[153]|new[155]	_	_
19-12	2710-2713	and	abstract[153]|abstract[155]	new[153]|new[155]	_	_
19-13	2714-2726	cytotoxicity	abstract[153]|abstract|abstract[155]	new[153]|new|new[155]	_	_
19-14	2727-2733	assays	abstract[155]	new[155]	_	_
19-15	2734-2738	have	_	_	_	_
19-16	2739-2743	been	_	_	_	_
19-17	2744-2751	carried	_	_	_	_
19-18	2752-2755	out	_	_	_	_
19-19	2756-2761	under	_	_	_	_
19-20	2762-2764	in	abstract[156]	new[156]	_	_
19-21	2765-2770	vitro	abstract[156]	new[156]	_	_
19-22	2771-2781	conditions	abstract[156]	new[156]	_	_
19-23	2782-2783	.	_	_	_	_

#Text=Comparative assessment of undoped and N-doped TiO2 nanoparticles has been performed to exploit the effectivity of these nanoparticles to be used as drug-loading agents or carriers in nanomedicine for the cure of countless fatal diseases disrupting human health .
20-1	2784-2795	Comparative	abstract[157]	new[157]	_	_
20-2	2796-2806	assessment	abstract[157]	new[157]	_	_
20-3	2807-2809	of	abstract[157]	new[157]	_	_
20-4	2810-2817	undoped	abstract[157]|object[159]	new[157]|giv[159]	coref	20-17[161_159]
20-5	2818-2821	and	abstract[157]|object[159]	new[157]|giv[159]	_	_
20-6	2822-2829	N-doped	abstract[157]|object[159]	new[157]|giv[159]	_	_
20-7	2830-2834	TiO2	abstract[157]|abstract|object[159]	new[157]|giv|giv[159]	_	_
20-8	2835-2848	nanoparticles	abstract[157]|object[159]	new[157]|giv[159]	_	_
20-9	2849-2852	has	_	_	_	_
20-10	2853-2857	been	_	_	_	_
20-11	2858-2867	performed	_	_	_	_
20-12	2868-2870	to	_	_	_	_
20-13	2871-2878	exploit	_	_	_	_
20-14	2879-2882	the	abstract[160]	new[160]	_	_
20-15	2883-2894	effectivity	abstract[160]	new[160]	_	_
20-16	2895-2897	of	abstract[160]	new[160]	_	_
20-17	2898-2903	these	abstract[160]|object[161]	new[160]|giv[161]	_	_
20-18	2904-2917	nanoparticles	abstract[160]|object[161]	new[160]|giv[161]	_	_
20-19	2918-2920	to	_	_	_	_
20-20	2921-2923	be	_	_	_	_
20-21	2924-2928	used	_	_	_	_
20-22	2929-2931	as	_	_	_	_
20-23	2932-2944	drug-loading	substance[162]|substance[163]	giv[162]|giv[163]	coref	20-23[163_162]
20-24	2945-2951	agents	substance[162]|substance[163]	giv[162]|giv[163]	_	_
20-25	2952-2954	or	substance[163]	giv[163]	_	_
20-26	2955-2963	carriers	substance[163]|organization[164]	giv[163]|new[164]	_	_
20-27	2964-2966	in	substance[163]|organization[164]	giv[163]|new[164]	_	_
20-28	2967-2979	nanomedicine	substance[163]|organization[164]|object	giv[163]|new[164]|new	_	_
20-29	2980-2983	for	_	_	_	_
20-30	2984-2987	the	event[166]	new[166]	_	_
20-31	2988-2992	cure	event[166]	new[166]	_	_
20-32	2993-2995	of	event[166]	new[166]	_	_
20-33	2996-3005	countless	event[166]|abstract[167]	new[166]|new[167]	_	_
20-34	3006-3011	fatal	event[166]|abstract[167]	new[166]|new[167]	_	_
20-35	3012-3020	diseases	event[166]|abstract[167]	new[166]|new[167]	_	_
20-36	3021-3031	disrupting	event[166]|abstract[167]	new[166]|new[167]	_	_
20-37	3032-3037	human	event[166]|abstract[167]|abstract[168]	new[166]|new[167]|new[168]	_	_
20-38	3038-3044	health	event[166]|abstract[167]|abstract[168]	new[166]|new[167]|new[168]	_	_
20-39	3045-3046	.	_	_	_	_
